EGFR and non-small cell lung carcinoma: Here, we review the post-osimertinib treatment options for EGFR-mutated NSCLC (Figure 1), providing an overview of ongoing clinical trials (Table 1) and proposing an algorithm to guide clinicians in managing progression on osimertinib.